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ABSTRACT
Severe acute respiratory syndrome corona virus 2 (SARS CoV 2) seems to display an increasing affinity for the nervous
system. The ongoing pandemic has made evident that diverse neurological manifestations may occur with COVID 19.
Headache and dizziness remain the most common symptoms however stroke, seizures, encephalopathy, neuropathy
and skeletal muscle injury may be seen. An increasing number of patients report initial anosmia and ageusia.
Tendency for serious illness is believed to be in the elderly or people with a history of diabetes, high blood pressure and
heart disease. Many patients on immunosuppressive therapies such as multiple sclerosis, myasthenia gravis or
sarcoidosis are additionally high risk. Angiotensin-converting enzyme 2 (ACE 2) has been identified as the cellular
receptor for SARS CoV 2 present in both neurons and glial tissue. The pathophysiology of neurotoxicity at best remains
elusive with dysregulation of homeostasis and pro inflammatory cytokine production causing direct, indirect and post
infectious neurological complications. Vigilant observation for neurological involvement is important not only to prevent
spread of this highly contagious disease but also for appropriate, timely management. A directed neurological
examination limiting exposure of medical personnel to potentially infected patients is mandatory. Appropriate
constrained investigations should be considered only if there is a likelihood of changing management. Tele neurology
consultations, whenever possible is the need of the hour. Outcomes of COVID 19 patients with severe illness and
neurological complications remains grave. Pharmaceutical research needs to change directions to expedite the
development of a possible vaccine and also accelerate in the quest for newer antiviral agents.
KEY WORDS: SARS-CoV2, COVID 19, ACE 2, Stroke , Seizures, neurological, meningitis

History of Corona Viruses:
Coronavirus disease was initially described in 1931,
with the first coronavirus (HCoV-229E) isolated from
humans in 1965. Until the outbreak of severe acute
respiratory syndrome (SARS CoV) in Guangdong, China
in 2002 only two human coronaviruses (HCoV) were
known – HCoV-229E and HCoV-OC43. More than 8000
SARS CoV cases were reported to the World Health
Organization (WHO) in 2002-03 and it caused
approximately 800 deaths worldwide with disease
identification in 29 countries, last case was seen in
2004. The Middle East respiratory syndrome
associated coronavirus (MERS-CoV) was the next
identified coronavirus in 2012 in Saudi Arabia. Larger
outbreaks have occurred later in South Korea in 2015
and in Saudi Arabia in 2018.About 2,500 cases have
been reported as of January 2020 from more than 26
countries causing approximately 900 deaths in total.
Viral genome analysis revealed that SARS-CoV belongs
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to Group B and MERS-CoV belongs to Group C beta
coronavirus, respectively, and both are closely related
to coronavirus strains found in bats.1
Intermediate mammalian hosts, such as civet cats,
have been implicated for SARS CoV before its
adaptation for human transmission, and evidence
through virus or antibody detection suggests that the
dromedary camels are likely the host for MERS-CoV.2
SARS-CoV-2 recently identified in Wuhan China in
December 2019 is a strain of SARS-CoV and it shares
the same receptor; angiotensin converting enzyme 2
(ACE2). It is believed to have zoonotic origins and has
close genetic similarity to bat coronaviruses.3
Epidemiology of COVID 19 and Burden of disease:
The WHO was informed of 44 cases of pneumonia of
unknown microbial etiology in Wuhan-Hubei China on
31 December 2019. Within a few weeks, the virus was
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identified as SARS CoV 2. Most of the patients in the
outbreak reported a link to the Huanan South China
Seafood and live animal Market. Rapid spread occurred
throughout China and within one month several other
countries, including Italy, the United States and
Germany. Since then, the outbreak has escalated
rapidly, with the WHO first declaring this as a public
health emergency of international concern on 30
January 2020 and then formally declaring it a
pandemic on 11 March 2020. Difficulty controlling
such an aggressive spread resulted partly due to the
extensive size of Wuhan; Central China’s transportation
hub, which has a full-time population of more than 9
million and a transient population of an additional 5.10
million. In an attempt to reduce virus transmission, on
January 23, 2020, authorities locked down Wuhan, but
by that time approximately 5 million persons had
already left.4 The WHO COVID-19 Situation Report for
April 21,2020 reports 2.4 million confirmed cases of
COVID 19 and 162,956 deaths.5 In Pakistan alone at
the writing of this manuscript the affected number was
approximately 10,513 with more than 224 mortalities.
All provinces in Pakistan have been affected with the
largest numbers from Punjab as per local authorities.
The incoming numbers have an increasing trend either
because of improved testing availability or because the
peak of this pandemic in Pakistan has not been
reached and the worst is yet to come.

Data from the largest case series in China found that
87% of confirmed cases were aged 30 to 79 years, 1%
were aged 9 years or younger, 1% were aged 10 to 19
years, and 3% were aged 80 years or older.
Approximately 51% of patients were male and 49%
were female.8 In the US, older patients (aged ≥65
years) accounted for 31% of all cases, 45% of
hospitalizations, 53% of intensive care unit admissions,
and 80% of deaths, with the highest incidence of
severe outcomes in patients aged ≥85 years.9 Infection
in children is reported much less commonly than
amongst adults.
Pathophysiology:
SARS CoV2 is an enveloped, positive sense, single
stranded RNA virus with a diameter of approximately
60-140 nanometers. The viral envelope consists of a
lipid bilayer with four structural proteins known as S
(spike (E (envelope), M (membrane) and N
(nucleocapsid). Interaction between the spike protein
and host cell receptor is essential for virulence and
infectivity.10 Following invasion of the lung epithelium,
SARS-CoV directly infects T cells and macrophages,
contributing to lymphopenia with reduced CD4+ and
CD8+ cell counts and dysregulation of normal adaptive
immune responses. Excessive production of
pro-inflammatory cytokines including interleukins (IL-1,
IL-6, IL-10), and tumor necrosis factor-alpha with
subsequent downregulation of anti- inflammatory
cytokines such as interferon gamma are thought to
contribute to excessive inflammation and activation of
pro-apoptotic pathway.11 In some cases, adaptive
immune responses might become directed against host
epitopes, resulting in post-infectious autoimmune
reactions that prolong the inflammatory phase and
induce tissue destruction even after the virus has been
cleared.

Demographics and Transmission:
As an emerging acute respiratory infectious disease,
COVID-19 primarily spreads through the respiratory
tract. Transmission occurs primarily via respiratory
droplets within a range of about 1.8 metres (6 ft).
Indirect contact via contaminated surfaces is another
possible cause of infection. The virus is inactivated by
soap, which destabilizes its lipid bilayer. Based on
current epidemiological investigation, the incubation
period is 1–14 days, mostly 3–7 days. The pharynx
reaches peak viral load approximately four days after
infection and the COVID-19 is contagious during the
latency period. It is highly transmissible in humans,
especially in the elderly and people with underlying
diseases like hypertension, ischemic heart disease and
diabetes mellitus. Each infection from the virus is
expected to result in 1.4 to 3.9 new infections when no
members of the community are immune and no
preventive measures are taken. Emerging evidence
suggests that ambient temperature has no significant
impact on the transmission of COVID-19; however,
further research is required on how weather conditions
influence transmission.6 The median age of patients is
47–59 years, and 41.9–45.7% of patients are
females.7
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Mechanisms of Neuronal injury:
Angiotensin-converting enzyme 2 (ACE 2) is the cellular
receptor for the new SARS-CoV-2 This is present in
multiple human organs including the brain and glial
tissue and thus this makes the central nervous system
a potential target.12 There may be direct infiltration of
the CNS through the nasal epithelium and entrance
into the olfactory pathway with the subsequent
retrograde trans-synaptic spread. Hematogenous
spread with secondary neurologic manifestations of
COVID-19 are thought to be the result of widespread
dysregulation of homeostasis and cytokine production
with pulmonary, renal, hepatic, and cardiovascular
injury.13. Besides coronavirus specific antibodies have
been shown to activate macrophages resulting in their
migration into the CNS and ultimately cause
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demyelination. Infection with COVID 19 promotes
atherosclerosis, inflammation and local thrombosis in
the presence of systemic inflammation the resultant
elevation in C reactive protein and D dimer increases
the risk of acute cerebrovascular disease.14 Molecular
mimicry between specific viral proteins and proteins
on peripheral nerves (gangliosides) leads to an
innocent bystander attack against the myelin or axon,
the most likely mechanism behind peripheral nerve
injury. There is no current evidence of direct viral
invasion with inflammation and degeneration of motor
neurons and peripheral nerves as seen in some other
viral infections like poliovirus, West Nile, Herpes
Zoster, or Cytomegalovirus etc.

hyposmia, and dysgeusia should be added to the list
of COVID-19 screening symptoms and urged
precautionary isolation for individuals with these
symptoms, even in the absence of respiratory
disease.16
Neurological syndromes:
Isolated new cases of COVID 19 with neurological
syndromes are emerging every day from all around
the world. Ischemic strokes have been reported in 5%
of patients with severe COVID -19 infections and in
1% of non-severe infections due to the COVID 19
from recent data considering the patients are in a pro
thrombotic state.3 There was also one patient with
spontaneous intra cerebral hemorrhage and cerebral
venous sinus thrombosis each in the same study.
Encephalopathy and acute hemorrhagic necrotizing
encephalopathy have recently been reported with
COVID19 which are rare complications of influenza
and
other
viral
infections.17
Myopathies,
rhabdomyolyis, viral myositis, critical illness myopathy
are all possibilities with COVID19. In recently
published studies from China myalgia developed in up
to 44% of hospitalized patients and elevated creatine
kinase in up to 33%.18 There is no proven direct
causality with Guillain Barre Syndrome as seen in
some other viruses like influenza, H1N1, ZIKA, EBV
etc. however some new case reports exist.19
Association with demyelination including Multiple
sclerosis and Acute disseminated encephalomyelitis
has been reported in the past.20

Neurological symptoms:
Neurological signs and symptoms fall into three main
categories; central nervous symptoms (CNS),
peripheral nervous symptoms (PNS) and skeletal
muscular symptoms.3 These clinical features may be
the presenting complaints or as more commonly seen
arise during the more frequently seen respiratory and
febrile illness. CNS manifestations most commonly
seen include dizziness, headache, impaired
consciousness, acute cerebrovascular disease,
ataxia, and seizures. PNS manifestations included
taste impairment, smell impairment and nerve pain.
Skeletal muscular injury manifestations include
myalgias. In the largest study to date on 214 patients
from Wuhan, China, overall, 78 patients (36.4%) had
neurologic manifestations. 126 patients (58.9%) had
non severe infection and 88 patients (41.1%) had
severe infection according to their respiratory status.
Patients with severe infection were more likely to
develop neurologic manifestations, especially acute
cerebrovascular
disease
[5.7%];
conscious
disturbance [14.8%] and skeletal muscle injury
[19.3%].3 Another recent report of 99 COVID-19
patients in Wuhan also described neurological
complications with confusion (9%) and headache
(8%) being most commonly seen.15 Most neurologic
manifestations occur early in the illness (median
time, 1-2 days). Of 6 patients with acute
cerebrovascular disease, 2 arrived at the emergency
department owing to the sudden onset of hemiplegia
but without any typical symptoms of fever, cough,
anorexia, and diarrhea of COVID-19. Their lung
lesions were found by an emergent lung CT and were
diagnosed as having COVID-19 by a positive
SARS-CoV-2 nucleic acid detection in the later
stage.3 Loss of smell and taste may precede
respiratory symptoms and suggest early neurological
involvement.
The
American
Academy
of
Otolaryngology recently proposed that anosmia,
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COVID-19 and Stroke
Acute strokes presenting in endemic areas in
emergency department may need to be checked for
COVID-19. The stroke team evaluating for patient
should divide to conserve personal protective
equipment and limit the potential for accidental
exposure. Patients needing tissue plasminogen
activator (tPA) during the one-hour infusion may be
monitored every 15 minutes by a single stroke team
member situated in the patient’s room. In cases of
mechanical thrombectomy, groin checks can be done
by team members entering for other reasons every 4
hours after the initial monitoring in the intervention
radiology suite.21
Non-contrast head CTs with
possible or confirmed COVID-19 should be reserved
for patients with significant change in neurologic
examination. Repeat imaging in neurologically stable
patients who have not received IV tPA or mechanical
thrombectomy should be avoided. Additional studies
including MRI, Echocardiogram’s and Doppler’s
should be considered only if likelihood of changing
management. Even in patients without COVID-19, the
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COVID 19 is still unknown. The risk of contamination
remains high. A non-contrast CT Head to exclude acute
stroke in patients with possible or confirmed COVID 19
should be reserved for times when actionable
information is likely to be obtained, or when a
significant change in the neurological examination is
seen. A CT angiogram of the head and neck may be
required in cases of subarachnoid hemorrhage.
Additional studies including MRI with gadolinium may
be required in patients with a history of seizures or
unexplained encephalopathy. In one recently published
study from Strasbourg, France, between March 3 and
April 3, 2020 in patients with confirmed COVID 19 with
encephalopathy. MRI Brain showed leptomeningeal
enhancement predominately in occipital lobe in eight
out of 13 patients. Small diffusion abnormalities
indicating asymptomatic acute ischemic stroke were
seen in two patients. Bilateral frontotemporal
hypo-perfusion was noted in all 11 of these patients
who underwent perfusion imaging.28 Hemorrhagic ring
enhancing lesions within the bilateral thalami and
medial temporal lobes on MRI Brain has been
described in a patient with acute hemorrhagic
encephalopathy.17

effectiveness of routine brain MRI to guide treatment
selection is uncertain.22
COVID-19 and Seizures
Metabolic derangements may be common in
SARS-CoV2 infected patients and these should be
evaluated for possibly causing seizures. Severely
affected have compromised renal and hepatic systems
and appropriate antiseizure medication should be
carefully
selected.
Brivaracetam,
lacosamide,
Levetiracetam, Zonisamide is advised with abnormal
liver tests.23
COVID19 and Headache
Headache appears to be the most common
neurological complaint with COVID-19. The putative
role of ACE2 in the pathophysiology has recently fueled
concerns regarding the use of non- steroidal
anti-inflammatory drugs (NSAIDs) such as ibuprofen,
commonly used for headache. These are known to
induce up-regulation of ACE2 and, in theory, may
facilitate infection with COVID-19.24 Sodium valproate
should be avoided amid to concerns of liver injury.
COVID-19 and GBS
All patients with suspected or diagnosed COVID-19 with
acute flaccid weakness should be admitted in intensive
care units. Elective endotracheal intubation should be
considered when single breath count test < 20, use of
accessory muscles or paradoxical breathing and neck
flexion weakness is noted. The generally considered
CSF analysis for cytological dissociation, maybe
warranted if it will change therapeutic decision as it
may be normal in one third to one half in first week of
symptoms. NCS 1-2 weeks after symptom onset
should be considered. Intravenous immunoglobulins
(IVIg) 2g/kg administered over 5 days is the standard of
care. Plasmapheresis over 5 cycles is an equally
efficacious alternative. Mild symptoms may not need
treatment; decision should be weighed against lengthy
hospital stay.25 The role of high dose IVIg in a recent
case series published with COVID-19, all of whom were
successfully treated at the early stage of clinical
deterioration with the resultant initiation of a
randomized controlled trial.26 This may lead us to
rethink the equal efficacy that has been long
established when treating patients with muscle or nerve
involvement with plasma exchange versus IVIg. Serial
PFTs (pulmonary function tests) at least q8h in first 24
hours. Daily vital sign, urine output, and last bowel
movement charting should be maintained for
anticipating autonomic dysfunction. 27

Cerebrospinal fluid:
A cerebrospinal fluid (CSF) examination may be
required to exclude possible causes of impaired
consciousness. All standard tests to exclude CNS
infections should be done simultaneously despite of
suspected encephalitis and encephalopathy due to
COVID-19. Cerebrospinal fluid is usually clear and
colorless with mild pleocytosis and lymphocytic
predominance. CSF oligoclonal bands may be present
with an identical electrophoretic pattern in serum28.
SARS-CoV-2 nucleocapsid protein genes can be
detected by using PCR and is recommended in highly
suspicious cases. In a recent case report with
meningitis the opening pressure of CSF was increased
up to 320 mmH2O. The CSF cell count was 12/µ L. 10
mononuclear and 2 polymorphonuclear cells without
red blood cells were noted. Although the specific
SARSCoV-2 RNA was not detected in the
nasopharyngeal swab of this patient, it was detected in
CSF.29
Electroencephalogram:
Electroencephalogram (EEG) may be needed in
unexplained drowsiness or with uncontrolled seizures.
Non-convulsive seizures seen in critically ill patients in
up to 10% .30 24 hour monitoring maybe required in
appropriate cases, ideally performed with disposable
EEG leads. Seizures were observed with other types of
coronavirus infections in up to 6 - 50% of affected

Neuroimaging
Although the full spectrum of neuro-imaging findings in
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children.31 The EEG findings although are non-specific
may show diffuse or bifrontal slowing consistent with
encephalopathy.28

but this remains to be seen in COVID-19.
Prognosis:
Neurological manifestations may have a variable
prognosis. Patients with milder disease or isolated
symptoms such as anosmia, ageusia, isolated
headaches or myalgias suggest a relatively better
outcome. However, those with more severe systemic
disease and extensive neurological involvement like
strokes, encephalitis or Guillain Barre syndrome may
have a graver outcome.

Nerve conduction studies and electromyography:
Nerve
conduction
studies
(NCS)
and
electromyography (EMG) may be necessary with
patient acute flaccid paralysis or myositis. Reports of
GBS in association with COVID-19 have recently been
seen.32 An over-emphasis on the fact that NCS and
EMG are within normal limits in the first 1-2 weeks in
diseases of the muscle and nerves cannot be made.
Unnecessary procedures should be avoided as the
machines may serve as fomites.

Future directions for research:
Understanding the full spectrum of the neurotropic
effects of COVID 19 is still in its maiden stages.
Neurological manifestations until now have depicted
the entire neuroaxis is prone to disease.
Pharmaceutical research needs to change directions
to expedite the development of a possible vaccine
and also accelerate in the quest for newer antiviral
agents. More extensive neurological workup or
autopsies and isolation of SARS CoV 2 from neural
tissue may help in aiding us to understand the
mechanism of COVID 19 better. Management
protocols may need to be revised as we learn more
about neurological complications every day.

Laboratory evaluation:
Laboratory findings in patients with COVID -19 include
high white blood cell counts, lower lymphocyte count,
and increased C-reactive protein. Severe infection
has corresponding higher D-dimer levels, increased
lactate dehydrogenase, alanine aminotransferase,
and aspartate aminotransferase levels, with elevated
blood urea nitrogen, creatinine levels and creatine
kinase (CPK) levels.
Management:
Patient with neurological manifestations and COVID
19 may require hospitalization with intensive care
monitoring. Minimal exposure of healthcare and still
providing the best possible care to patients should be
the aim.

CONCLUSION:
A multi-disciplinary approach is required to control
this massive challenge faced by humanity. Health
care providers should keep a close watch for isolated
neurological symptoms at presentation when
evaluating patients for COVID 19 to assure both
appropriate management and control of disease. A
directed neurological examination limiting exposure of
medical personnel to potentially infected patients is
mandatory. Appropriate constrained investigations
should be considered only if there is a likelihood of
changing management. Research for new anti-viral
drugs and the development of a possible vaccine is
cardinal for the management. Tele neurology
consultations whenever possible is the need of the
hour. Outcomes of COVID 19 patients with severe
illness and neurological complications remains grave

Long term neurological complications of SARS
and other corona viruses:
Delayed neurologic sequelae after 2 weeks of
respiratory issues have been described following both
SARS-CoV-1 and MERS-CoV infection, such as
peripheral
neuropathy,
myopathy,
Bickerstaff
brainstem encephalitis, and GBS.33,34
Although there is limited data for COVID-19-related
psychiatric symptoms currently, survivors of
SARS-CoV
were
clinically
diagnosed
with
post-traumatic stress disorder (54.5%), depression
(39%), pain disorder (36.4%), panic disorder
(32.5%), and obsessive compulsive disorder (15.6%)
at 31 to 50 months post-infection, a dramatic
increase from their pre-infection prevalence of any
psychiatric diagnoses of 3%.35 Parkinsonism is a late
feature of encephalitis lethargica, first described
following the influenza pandemic of 1918.36 While
features of Parkinsonism have not been described in
association with CoV outbreaks, anti-CoV antibodies
have been identified in CSF of individuals with
Parkinson’s disease. It is plausible that this could
contribute to a delayed neurodegenerative process
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